Evidence map›Paper›PMID 41815862›Full record

ReviewMaterials today. Bio2026

PMPCylated liposomes in drug delivery and beyond.

Yannan Shi, Zhuoxun Huang, Siyi Zhu, Qing Yao, Jingxin Gou, Longfa Kou

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yannan ShiHuzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Affiliated Central Hospital of Huzhou University, Huzhou, China.
Zhuoxun HuangWenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
Siyi ZhuWenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
Qing YaoWenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
Jingxin GouDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Longfa KouWenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) is a zwitterionic polymer that mimics phosphatidylcholine headgroups of cell membrane, exhibiting excellent biocompatibility and antifouling properties. Recently, PMPCylated liposomes, i.e., liposomes functionalized with PMPC chains, have emerged as promising nanocarrier for drug delivery and other biomedical applications. This review summarizes recent progress in the design and application of PMPCylated liposomes, with a focus on their roles in prolonging systemic circulation, enhancing immune evasion, improving boundary lubrication for joint therapy, and overcoming biological barriers such as mucus and BBB. PMPC coatings outperform traditional PEGylation (polyethylene glycol, PEG) by more effectively minimizing protein adsorption, avoiding immune recognition, and enabling repeatable administration without accelerated clearance. Intra-articular PMPCylated liposomes exhibit superlubrication and cartilage adherence, offering both mechanical protection and therapeutic potential in osteoarthritis. In parallel, the hydration layer formed by PMPC facilitates mucus penetration and biofilm disruption, expanding its utility in oral, infectious, and neurological drug delivery. Finally, the clinical translational potential and future design strategies are discussed. Together, these findings highlight PMPCylated liposomes as a versatile and promising platform for drug delivery and beyond.

Indexed as

Barrier penetrationDrug delivery systemsImmune evasionJoint lubricationPMPCylated liposomesZwitterionic polymers

Identifiers

PMID41815862
PMCPMC12972538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.